Peter Adamson, MD on Isatuximab-irfc for Patients with RR/MM: How Is This Different?

Peter Adamson, MD on Isatuximab-irfc for Patients with RR/MM: How Is This Different?

User Photo
Cancer-News

4 weeks
3 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Up Next Autoplay
User Photo